Baxter Receives Approval to Process ARALAST NP
Baxter received Food and Drug Administration approval to transfer ARALAST processing from a third party to Baxter. ARALAST NP is a brand name referring to the therapy completely processed by Baxter. It is biologically equivalent to currently marketed ARALAST.
ARALAST is a human alpha1 - proteinase inhibitor (A1PI) indicated for chronic augmentation therapy in patients with hereditary emphysema, which is a genetic condition caused by a deficiency of A1PI in the lungs. People with this deficiency have reduced serum levels of A1PI, an important blood protein processed in the liver that can protect lung tissue from damage caused by enzymes that are released by white blood cells. Alpha1-Antitrypsin deficiency affects an estimated 60,000 to 100,000 people in the United States. It is estimated more than 95 percent of those with AAT deficiency are undiagnosed. Without sufficient quantities of A1PI, patients develop lung damage. If untreated, A1PI deficiency can result in emphysema and premature death.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.